The Nanoparticle That Finally Found the Heart

METiS TechBio achieves ~100% cardiac cell delivery via AI-designed LNPs in a world-first preclinical result

20 May 2026

Getting genetic medicines to heart muscle through the bloodstream has been among the field's most persistent technical failures. Lipid nanoparticles given intravenously tend to concentrate in the liver, bypassing cardiac tissue almost entirely. METiS TechBio said on Thursday its AI-powered NanoForge platform had achieved close to complete delivery into cardiomyocytes, with significant gene editing activity observed in preclinical tests.

The company's data have been selected for a late-breaking oral presentation at the 2026 Controlled Release Society Annual Meeting in Lisbon this July. NanoForge combines AI-driven lipid discovery, formulation optimisation, and targeting ligand engineering to redirect nanoparticles toward the heart following intravenous injection.

"Extrahepatic delivery remains one of the most important challenges in genetic medicine," said Dr. Chris Lai, chief executive of METiS TechBio.

No non-viral delivery system has previously reported approximately 100% cardiomyocyte transfection via systemic injection. Viral vectors have historically carried immunogenicity risks and manufacturing costs that limit their use at scale. A non-viral platform capable of cardiac precision, if validated further, would address both constraints.

Full technical scrutiny arrives in Lisbon in July, where the data face independent peer review for the first time. Selection as a late-breaking presentation signals the findings were judged sufficiently novel to warrant priority placement on the programme.

METiS TechBio listed on the Hong Kong Stock Exchange on 13 May 2026, raising more than HKD 2.1 billion in what it said was Hong Kong's largest healthcare initial public offering this year. The offering was oversubscribed more than 6,900 times. Whether the preclinical results translate into human trials will determine whether the investor confidence was well placed.